The FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.
from Food and Drug Administration--Press Releases https://ift.tt/2QkDF2v
via IFTTT
No comments:
Post a Comment